Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
Should You Buy Jazz Pharmaceuticals (JAZZ) Ahead of Earnings?
02:57pm, Monday, 04'th May 2020
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Jazz Pharmaceuticals (JAZZ) Ahead of Earnings?
12:00am, Monday, 04'th May 20202 Cheap Healthcare Stocks to Buy Now
11:36am, Sunday, 03'rd May 2020
It's time to shop for healthcare stocks that have suffered so far this year but should rebound in the long term thanks to growth drivers waiting in the wings. The first of these great deals, a pharma
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
The NBA Is Optimistic About Its Return. Here’s Why That Should Matter To You
01:28pm, Friday, 01'st May 2020
By actively and optimistically pursuing a smart and safe restart, the NBA is doing what some of our own elected officials have not been able to do – create a sense of possibility even while explorin
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Sees Large Increase in Short Interest
08:46am, Friday, 01'st May 2020
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 2,950,000 shares, a growth
Jazz Pharma comes up empty in late-stage defibrotide study
01:22pm, Thursday, 30'th Apr 2020
Jazz Pharmaceuticals (NASDAQ:JAZZ) slips 3% premarket on light volume on the heels of disappointing results from a Phase 3 clinical trial evaluating defibrotide for the prevention of hepatic veno-oc
Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $162
12:00am, Thursday, 30'th Apr 2020BRIEF-Jazz Pharma Stops Enrollment In Phase 3 Study Evaluating Defibrotide For Prevention Of Veno-Occlusive Disease
08:25pm, Wednesday, 29'th Apr 2020
Jazz Pharmaceuticals PLC:
Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease
08:05pm, Wednesday, 29'th Apr 2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-
Jazz Pharmaceuticals stops enrollment in Phase 3 study of defibrotide JAZZ
09:13am, Wednesday, 29'th Apr 2020
Jazz Pharmaceuticals stops enrollment in Phase 3 study of defibrotide JAZZ
Jazz Pharmaceuticals Stops Enrollment For Its Phase 3 Study Evaluating Defibrotide For The Prevention Of Veno-Occlusive Disease
12:00am, Wednesday, 29'th Apr 2020At His Centennial, a Jazz Pioneer Still Rings True
08:19pm, Tuesday, 28'th Apr 2020
John Lewis was a visionary pianist who imagined a different look, sound and esteem for jazz.
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04:33pm, Tuesday, 28'th Apr 2020
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04:33pm, Tuesday, 28'th Apr 2020
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
